Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Article / By

This Phase I trial evaluated the combination of ribociclib (a CDK4/6 inhibitor) and spartalizumab (a PD-1 inhibitor) with and without fulvestrant in patients with metastatic hormone receptor-positive breast cancer or advanced ovarian cancer. The study found that while the recommended phase 2 dose of ribociclib was established at 600 mg, the treatment showed limited efficacy and increased hepatotoxicity, leading to the conclusion that further development is not warranted.

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer Read More »

Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4–6 inhibitors?

Article / By

The research investigates the potential of macrocytosis as a biomarker for predicting progression-free survival (PFS) and overall survival (OS) in patients with hormone-positive metastatic breast cancer treated with CDK 4-6 inhibitors. The study found that macrocytosis significantly affects both PFS and OS, suggesting its utility in clinical outcomes for these patients.

Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4–6 inhibitors? Read More »

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Article / By

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Read More »

European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care

Article / By

The European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance have developed the first set of quality indicators for metastatic breast cancer care to ensure that breast cancer centers meet required standards. A multidisciplinary group of experts identified and defined these indicators, focusing on aspects such as access to care, disease characterization, and treatment protocols. This initiative aims to improve the quality of care for patients with metastatic breast cancer through routine measurement and evaluation.

European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care Read More »

An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)

Article / By

This review highlights the clinical development of therapies targeting ERBB2-low breast cancer, which constitutes about 50% of cases but is currently ineligible for anti-ERBB2 treatments. It discusses the potential of novel therapies like trastuzumab deruxtecan and the need for revised diagnostic criteria to better identify and treat patients with ERBB2-low tumors. Ongoing research may lead to improved strategies for managing this distinct breast cancer subtype.

An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low) Read More »

Start typing and press enter to search

This site is only for use by healthcare professionals.

By continuing to view this site you are confirming that you are a healthcare professional.

Confirm